EUVIMEDEUVIMED entdecken
Crossref

18F-labelled gentiobiose as potential PET-radiotracer for specific bacterial imaging: precursor synthesis, radiolabelling and in vitro evaluation

Felicitas Landau, Sven Hermann, Sonja Schelhaas, Michael Schäfers, Silke Niemann, Andreas Faust

Nuklearmedizin - NuclearMedicine · 01.10.2024 · 63 (05) · 300-305

DOI: 10.1055/a-2365-8054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.10.2024. Verfasst von Felicitas Landau und 5 weiteren Autor:innen. Beteiligte Einrichtung: European Institute for Molecular Imaging, University of Münster, Münster, Germany. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Fluorine Radioisotopes, Disaccharides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Bacterial infections are a clinical challenge, requiring fast and specific diagnosis to ensure effective treatment. Therefore, this project is dedicated to development of positron emission tomography (PET) radiotracers specifically targeting bacteria. Unlike previously developed bacteria-specific radiotracers, which are successful in detecting Gram-negative bacteria, tracers capable of imaging Gram-positive infections are still lacking.

Methods

The disaccharide gentiobiose as abundant part of the cell wall of Gram-positive bacteria could fill this gap. Herein, the synthesis and evaluation of 2‘-deoxy-2‘-[18F]fluorogentiobiose ([18F]FLA280) is reported. The precursor for radiolabelling was obtained from a convergent synthesis under application of a benzylidene/benzyl group protecting strategy.

Results

The first catalytic hydrogenation in 18F-radiochemistry is reported as proof of concept. The deprotection was carried out without any side product formation, giving the final radiotracer [18F]FLA280 in good radiochemical yield and excellent radiochemical purity. [18F]FLA280 was proven to be stable in murine and human blood serum for 120 minutes and was subjected to in vitro bacterial uptake studies towards S. aureus and E. coli resulting in a low bacterial uptake.

Conclusion

The observed bacterial uptake indicates that [18F]FLA280 may be not a promising tracer candidate for in vivo translation and alternative candidates particularly for Gram-positive bacteria are required. However, further development on the concept of labelled carbohydrates and cell wall building blocks might be promising.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyFluorine RadioisotopesDisaccharidesMiceHumansAnimalsIsotope LabelingRadiopharmaceuticalsEscherichia coli

Substanzen

Fluorine RadioisotopesDisaccharidesRadiopharmaceuticalsFluorine-18

Autor:innen und Institutionen

  • European Institute for Molecular Imaging, University of Münster, Münster, Germany.
  • Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
  • Institute of Medical Microbiology, University Hospital Münster, Münster, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Landau, F., Hermann, S., Schelhaas, S., Schäfers, M., Niemann, S., & Faust, A. (2024). 18F-labelled gentiobiose as potential PET-radiotracer for specific bacterial imaging: precursor synthesis, radiolabelling and in vitro evaluation. Nuklearmedizin - NuclearMedicine, 63(05), 300-305. https://doi.org/10.1055/a-2365-8054

Vancouver

Landau F, Hermann S, Schelhaas S, Schäfers M, Niemann S, Faust A. 18F-labelled gentiobiose as potential PET-radiotracer for specific bacterial imaging: precursor synthesis, radiolabelling and in vitro evaluation. Nuklearmedizin - NuclearMedicine. 2024;63(05):300-305. doi:10.1055/a-2365-8054

BibTeX
@article{Landau2024,
  author = {Landau, Felicitas and Hermann, Sven and Schelhaas, Sonja and Schäfers, Michael and Niemann, Silke and Faust, Andreas},
  title = {18F-labelled gentiobiose as potential PET-radiotracer for specific bacterial imaging: precursor synthesis, radiolabelling and in vitro evaluation},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2024},
  volume = {63},
  number = {05},
  pages = {300--305},
  doi = {10.1055/a-2365-8054}
}
Kostenlos starten →